In the Journals

PCV13 vaccine deemed effective in preventing pneumococcal disease

The majority of pediatric patients who received the 13-valuent pneumococcal conjugate vaccine in this study showed no signs of pneumococcal disease indicated by various serotypes, according to recent research.

“In summary, 13-valent pneumococcal conjugate vaccine (PCV13) was found to be highly effective in preventing invasive pneumococcal disease among young children in the United States,” Matthew R Moore, MD, from the National Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention in Atlanta, and colleagues wrote in their study. “By preventing disease caused by serotype 19A and other resistant strains, PCV13 immunisation provides a robust strategy for combating antimicrobial resistance.”

Moore and colleagues evaluated 722 children with invasive pneumococcal disease against 2,991 patients in a control group, according to the abstract. The PCV13 serotypes most commonly found in the children were 19A (128 patients; 18%), 7F (32 patients; 4%) and 3 (43 patients; 6%), while non-PCV13 serotypes most commonly found were 22F (84 patients; 17%), 33F (62 patients; 12%), 15C (46 patients; 9%) 15B (40 patients; 8%) and 35B (40 patients; 8%).

As part of a post-licensure evaluation of PCV13, the primary outcome for researchers was immunity against one dose or more of the 13 serotypes in PCV13, with a secondary outcome of immunity against all-cause invasive pneumococcal disease, as well as against antibiotic non-susceptible invasive pneumococcal disease.

They found a vaccine effectiveness of 86% for PCV13 serotypes (95% CI, 75.5%-92.3%) with the highest effectiveness seen for serotypes 19A (85.6%; 95% CI, 70.6%-93.5%) and 7F (96.5%; 95% CI, 82.7%-100%), according to the abstract. Moore and colleagues also found the vaccine was significantly effective against serotype 3 (79.5%; 95% CI, 30.3%-94.8%) and against antibiotic non-susceptible invasive pneumococcal disease (65.6%; 95% CI, 44.9%-78.7), as well as against all-cause invasive pneumococcal disease (60.2%; 95% CI, 46.8%-70.3%). The researchers noted the vaccine was effective for children with both underlying (81.4%; 95% CI, 45.4%-93.6%) and non-underlying conditions (85.8%; 95% CI, 74.9%-91.9%). – by Jeff Craven

Disclosure: Link-Gelles and Holtzman received grants from Centers for Disease Control and Prevention. The other researchers report various financial disclosures. Please see the full study for a complete list of disclosures.

The majority of pediatric patients who received the 13-valuent pneumococcal conjugate vaccine in this study showed no signs of pneumococcal disease indicated by various serotypes, according to recent research.

“In summary, 13-valent pneumococcal conjugate vaccine (PCV13) was found to be highly effective in preventing invasive pneumococcal disease among young children in the United States,” Matthew R Moore, MD, from the National Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention in Atlanta, and colleagues wrote in their study. “By preventing disease caused by serotype 19A and other resistant strains, PCV13 immunisation provides a robust strategy for combating antimicrobial resistance.”

Moore and colleagues evaluated 722 children with invasive pneumococcal disease against 2,991 patients in a control group, according to the abstract. The PCV13 serotypes most commonly found in the children were 19A (128 patients; 18%), 7F (32 patients; 4%) and 3 (43 patients; 6%), while non-PCV13 serotypes most commonly found were 22F (84 patients; 17%), 33F (62 patients; 12%), 15C (46 patients; 9%) 15B (40 patients; 8%) and 35B (40 patients; 8%).

As part of a post-licensure evaluation of PCV13, the primary outcome for researchers was immunity against one dose or more of the 13 serotypes in PCV13, with a secondary outcome of immunity against all-cause invasive pneumococcal disease, as well as against antibiotic non-susceptible invasive pneumococcal disease.

They found a vaccine effectiveness of 86% for PCV13 serotypes (95% CI, 75.5%-92.3%) with the highest effectiveness seen for serotypes 19A (85.6%; 95% CI, 70.6%-93.5%) and 7F (96.5%; 95% CI, 82.7%-100%), according to the abstract. Moore and colleagues also found the vaccine was significantly effective against serotype 3 (79.5%; 95% CI, 30.3%-94.8%) and against antibiotic non-susceptible invasive pneumococcal disease (65.6%; 95% CI, 44.9%-78.7), as well as against all-cause invasive pneumococcal disease (60.2%; 95% CI, 46.8%-70.3%). The researchers noted the vaccine was effective for children with both underlying (81.4%; 95% CI, 45.4%-93.6%) and non-underlying conditions (85.8%; 95% CI, 74.9%-91.9%). – by Jeff Craven

Disclosure: Link-Gelles and Holtzman received grants from Centers for Disease Control and Prevention. The other researchers report various financial disclosures. Please see the full study for a complete list of disclosures.